Showing results (1011-1020 of 1,104) with videos related to
Sort By:
Pageof 111
Cancer Medicine|January 20, 2025
Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary TractMohammad Jad Moussa, Georges C Tabet, Arlene O Siefker-Radtke, et al.The Lancet. Oncology|November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trialChristopher J Logothetis, Ethan Basch, Arturo Molina, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on EnzalutamideWassim Abida, Andrew W Hahn, Neal Shore, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2020
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate CancerPaul G Corn, Miao Zhang, Graciela M Nogueras-Gonzalez, et al.Frontiers in Pharmacology|April 25, 2018
Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A<sub>2A</sub>-Dopamine D<sub>2</sub> Receptor Heterotetramers and Adenylyl CyclaseSergi Ferré, Jordi Bonaventura, Wendy Zhu, et al.The Journal of Clinical Investigation|July 12, 2008
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanismsZhi Gang Li, Paul Mathew, Jun Yang, et al.Cell|November 29, 2011
Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugsMiguel Fribourg, José L Moreno, Terrell Holloway, et al.European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastasesY Loriot, L Pagliaro, A Fléchon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.BJU International|June 11, 2015
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillanceJohn W Davis, John F Ward, Curtis A Pettaway, et al.Pageof 111